This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2013 Feb;88(2):126-8.

doi: 10.1016/j.mayocp.2012.12.005.

Preventing adverse drug-drug interactions: a need for improved data and logistics

Michael J Seminerio, Mark J Ratain

PMID: 23374616
DOI: 10.1016/j.mayocp.2012.12.005

Editorial

Preventing adverse drug-drug interactions: a need for improved data and logistics

Michael J Seminerio et al. Mayo Clin Proc. 2013 Feb.

. 2013 Feb;88(2):126-8.

doi: 10.1016/j.mayocp.2012.12.005.

Authors

Michael J Seminerio, Mark J Ratain

PMID: 23374616
DOI: 10.1016/j.mayocp.2012.12.005

No abstract available

PubMed Disclaimer

Comment on

Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents.
Bowlin SJ, Xia F, Wang W, Robinson KD, Stanek EJ. Bowlin SJ, et al. Mayo Clin Proc. 2013 Feb;88(2):139-48. doi: 10.1016/j.mayocp.2012.10.020. Mayo Clin Proc. 2013. PMID: 23374617

Similar articles

Survey of immunisation practices in the United Kingdom during and following completion of anti-cancer chemotherapy in children.
Mahajan A, English MW, Jenney ME, Foot A. Mahajan A, et al. Med Pediatr Oncol. 2003 Apr;40(4):270-1. doi: 10.1002/mpo.10152. Med Pediatr Oncol. 2003. PMID: 12555265 No abstract available.
Targeted therapy at the end of life for patients with lung cancer.
Wong AS, Teo C, Lim SW, Wong E, Soo RA, Chan N. Wong AS, et al. J Palliat Med. 2010 Aug;13(8):945-8. doi: 10.1089/jpm.2010.0084. J Palliat Med. 2010. PMID: 20712464
Emerging trends in combinations of gefitinib and cytotoxic agents: new opportunities.
Tabernero J, Macarulla T. Tabernero J, et al. Onkologie. 2005 Oct;28(10):467-70. doi: 10.1159/000088154. Onkologie. 2005. PMID: 16285032 No abstract available.
Quality of Life Matters: It Is Time to Integrate Scalp Cooling in Routine Clinical Practice.
Nangia J. Nangia J. J Oncol Pract. 2018 Mar;14(3):157-158. doi: 10.1200/JOP.18.00033. J Oncol Pract. 2018. PMID: 29529388 Review. No abstract available.
Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use.
Gougis P, Palmieri LJ, Funck-Brentano C, Paci A, Flippot R, Mir O, Coriat R. Gougis P, et al. Crit Rev Oncol Hematol. 2019 Sep;141:112-124. doi: 10.1016/j.critrevonc.2019.06.006. Epub 2019 Jun 16. Crit Rev Oncol Hematol. 2019. PMID: 31276964 Review.

See all similar articles

Cited by

A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients.
Patel N, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA, Miller C. Patel N, et al. Infect Dis Ther. 2015 Jan 28;4(1):67-78. doi: 10.1007/s40121-015-0058-x. Online ahead of print. Infect Dis Ther. 2015. PMID: 25708155 Free PMC article.
Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.
Teo YL, Ho HK, Chan A. Teo YL, et al. Br J Clin Pharmacol. 2015 Feb;79(2):241-53. doi: 10.1111/bcp.12496. Br J Clin Pharmacol. 2015. PMID: 25125025 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations